DEVOTE

Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating an Active Drug in Routine Clinical Practice

Brief summary

A study to assess the real-life management and use of healthcare resources during the initiation of:

- Active drug in combination with rituximab is indicated for the treatment of adult participants with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

- Active drug in participants with CLL with the deletion of the short arm of chromosome 17 (del[17p]) who have received at least 1 prior therapy or participants with CLL without del(17p) who have received at least 1 prior therapy and for whom there are no other available treatment options.

Interventional study

Status:
Recruiting
Conditions:
Chronic Lymphocytic Leukemia
Enrollment:
70 patients
Protocol ID:
P16-489
Observational model:
Cohort
Time perspective:
Prospective

Would you like to know more about this trial?

Yes, please contact me

Eligibility criteria

Participant attributes:
Male and Female

Age:

18 Years and older.

Inclusion Criteria:

- Patient's physician prescribed venetoclax as per product monograph independent of the
patient participation in this study.

- Has chronic lymphocytic leukemia (CLL) and has received at least one prior therapy.

Exclusion Criteria:

- Currently participating in an interventional study.

- Has other condition that, in the opinion of the treating physician, prohibits the
patient from participating in the study or obscures the assessment of the treatment of
CLL.

All the cities where the clinical studies are located

Calgary - T2N 4Z6

Edmonton - T6G 1Z2

Lethbridge - T1J 1W5

Halifax - B3H 1V7

Brampton - L6R 3J7

Kingston - K7L 2V7

Ottawa - K1H 8L6

Sudbury - P3N 1H5

Thunder Bay - P7B 6V4

Montreal - H3T 1E2

Rimouski - G5L 5T1

Moncton - E1C 6Z8

Manitoba - R3E 0V9